Individualized Therapy For Asthma in Toddlers

PHASE3CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
AsthmaWheezing
Interventions
DRUG

daily fluticasone propionate

Flovent® HFA, 44 mcg per inhalation, 2 inhalations twice daily

DRUG

Montelukast

Singulair®, 4 mg granules or chewable tablets by mouth once daily in the evening

DRUG

as-needed fluticasone propionate

Flovent® HFA, 44 mcg per inhalation, 2 inhalations, as needed for asthma symptoms

Trial Locations (13)

15224

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

22908

University of Virginia Health System, Charlottesville

30322

Emory University, Atlanta

44106

Rainbow Babies and Children's Hospital, Case Western Reserve University, Cleveland

53792

University of Wisconsin-Madison, Madison

60612

Rush University Medical Center/Stroger Hospital, Chicago

60614

Children's Memorial Hospital, Chicago

63110

St. Louis Children's Hospital, St Louis

80206

National Jewish Health, Denver

85724

University of Arizona College of Medicine, Tucson

94143

UCSF Benioff Children's Hospital, San Francisco

94609

Children's Hospital & Research Center Oakland, Oakland

02115

Children's Hospital, Boston, Boston

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Milton S. Hershey Medical Center

OTHER

NCT01606306 - Individualized Therapy For Asthma in Toddlers | Biotech Hunter | Biotech Hunter